| Followers | 18 |
| Posts | 1681 |
| Boards Moderated | 0 |
| Alias Born | 09/10/2014 |
Thursday, December 10, 2015 3:11:46 PM
This is just my opinion, but anonymous accusations against a non-UK publicly traded company, not on the London stock exchange does not seem very newsworthy, certainly not to the degree of ink that was garnered over this story and which is still generating articles. Woodford/Ondra went out of their way to make it newsworthy, and I believe, has kept the story alive, possibly pushing it to pressure the company to let in his "Wolves" before NWBO had a chance to fully vet them. Consider the pressure that was being applied....If she had buckled and not vetted these individuals and companies, he could have taken the company down!
One has to question...why the pressure, why the rush to make the certain and specific appointments he was insisting on.....it still looks like an aggressive agenda to me. One that would have generated tremendous hostility toward Linda right before the board meeting if it had been successful and negative actions had resulted from Wolf's document dump. I cannot see how his actions in any way were intended to protect the value of the company and shareholders. I may be wrong, but it seemed to be a seek and destroy mission, with the aim to destabilize management and potentially take over, as he tried to do in other situations.
One has to question...why the pressure, why the rush to make the certain and specific appointments he was insisting on.....it still looks like an aggressive agenda to me. One that would have generated tremendous hostility toward Linda right before the board meeting if it had been successful and negative actions had resulted from Wolf's document dump. I cannot see how his actions in any way were intended to protect the value of the company and shareholders. I may be wrong, but it seemed to be a seek and destroy mission, with the aim to destabilize management and potentially take over, as he tried to do in other situations.
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
